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Abstract
Background: The product of the retinoblastoma-susceptibility gene (pRb) is a substrate for
Protein Phosphatase 1 (PP1). At mitotic exit, all three PP1 isoforms, α, γ1 and δ, bind to pRb and
dephosphorylate its Ser/Thr sites in a sequential and site-specific way. The pRb-C terminal has been
reported to be necessary and sufficient for PP1α binding. The present study investigated whether
the three PP1 isoforms from mitotic or asynchronous HeLa cells associate differentially with wild-
type and pRb mutants, as well as the holoenzyme composition of the pRb-directed PP1.
Results:  The requirement for the entire pRb molecule to achieve optimal PP1-binding was
indicated by the fact that full-length pRb displayed the highest affinity for all three PP1 isoforms. Ser/
Thr-to-Ala substitution for up to 14 pRb sites did not affect the ability of pRb to bind the PP1
isoforms derived from mitotic or asynchronous HeLa cells, thus suggesting that the phosphate-
accepting residues on pRb do not regulate the interaction with PP1. To probe for the presence of
PP1 targeting subunits in the pRb-directed PP1 complex, PP1 from mitotic or asynchronous HeLa
cells was isolated by affinity chromatography on GST-Rb (either full-length or its deletion mutants
Rb-big pocket or Rb-C-terminal). The PP1 was always obtained as free catalytic subunit, displaying
all three isoforms, thus suggesting direct interaction between pRb and PP1. The direct association
was confirmed by the ability of pRb to pull-down purified PP1 catalytic subunits and by in vitro
reconstitution of a complex between PP1 catalytic subunit and the pRb-C-terminal.
Conclusion: The work indicated that the full length of the pRb molecule is required for optimal
interaction with the PP1 isoforms and that the association between pRb and PP1 isoforms is direct.
Background
Type 1 protein phosphatase (PP1), one of the major cellu-
lar serine/threonine phosphatases, is abundantly
expressed in virtually all cell compartments [1]. PP1 plays
a key role in the regulation of cell cycle progression and is
also involved in other processes, including gene expres-
sion, muscle contraction, glycogen metabolism and neu-
rotransmission [2,3]. The PP1 holoenzyme generally
consists of a catalytic subunit bound to a regulatory subu-
nit. Various unrelated regulatory subunits were described,
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which modulate the catalytic activity and restrict its sub-
cellular localization [1,2]. Three PP1 catalytic subunits
exist in mammalian cells, α, γ1 and δ (also called β). In
spite of being different gene products, these isoforms dif-
fer significantly only at their C-termini [4]. Using isoform-
specific antibodies developed in this laboratory, these
subunits were found to differ in sub-cellular localization,
suggesting that they perform different functions [5,6].
One of the physiological substrates of PP1 is the product
of the retinoblastoma gene, pRb [7], which controls cell
proliferation by regulating the G1-S-phase transition
[7,8]. pRb interacts with a variety of cellular proteins
dependent upon the phosphorylation state of its 16 Ser/
Thr residues. These residues are generally sites of cyclin-
dependent kinase (Cdk) phosphorylation [9], which var-
ies as a function of cell cycle phase [10-12]. During early
G1, pRb is hypophosphorylated and active as growth sup-
pressor. Hypo-phosphorylated pRb complexes with and
sequesters the E2F family of transcription factors, thereby
preventing the transcription of genes required for S-phase
entry [13]. In middle to late G1, phosphorylation of pRb
by Cdks results in the release and activation of E2F and
other pRb-bound transcription factors, which than acti-
vate the transcription of S-phase genes [14]. During the M-
to-G1 transition, pRb is progressively dephosphorylated
by PP1, returning to its growth-suppressive hypophos-
phorylated state [15-18].
Earlier studies suggested that among the PP1 isoforms,
PP1δ has the greatest pRb-directed phosphatase activity
[15] and co-immunoprecipitates with pRb from mitotic
and early G1 cells [19]. However, detailed studies in cells
at mitotic exit indicated that all three PP1 isoforms
dephosphorylate pRb, and that targeting of specific sites is
temporally-regulated [6]. The PP1 catalytic subunit itself
is subjected to inhibitory phosphorylation by Cdks, thus
preventing its premature activation and allowing coordi-
nated cell cycle progression [20-23].
The carboxyl terminal region of pRb has been found to be
both necessary and sufficient for the interaction with
PP1α [24]. However, mitotic PP1 also dephosphorylates
Ser/Thr residues located outside the pRb carboxyl termi-
nus [6], suggesting an interaction with additional pRb
domains. The mitotic pRb-directed PP1 has been
described as a high molecular weight complex, suggesting
the presence of a PP1 regulatory subunit which would tar-
get PP1 to pRb and contribute to enzyme regulation [15].
Though some candidates were proposed (e.g. PP1 nuclear
targeting subunits, [17]), the presence and precise identi-
fication of such a regulatory subunit may be argued.
In the present work, we investigated the association
between pRb and the PP1 isoforms, as well as the presence
of PP1 regulatory subunits associated with the pRb-
directed PP1. We report that the entire pRb molecule is
required for optimal in vitro interaction with the PP1 iso-
forms derived from cell extract and that this interaction is
a direct one.
Results
Association of PP1 from mitotic HeLa cell extracts with 
recombinant pRb [Fig 1]
The carboxyl terminal region of pRb (residues 792–928)
has been reported to be both necessary and sufficient for
in vitro complex formation with PP1α [24]. However, the
PP1 isoforms also dephosphorylate sites located in the A/
B big pocket and N-terminal regions of pRb [6], (depicted
in the lower part of Fig 2). To investigate whether the
entire pRb molecule was required for binding the PP1 iso-
Association of mitotic PP1 isoforms with Rb or Rb-deletion  mutants Figure 1
Association of mitotic PP1 isoforms with Rb or Rb-
deletion mutants. The GST-Rb fusion proteins, full-length 
(Rb) and big pocket (RbBP), or the pMAL-Rb fusion proteins, 
RbBP and carboxyl terminus (RbCT; also indicated in the 
lower part of the figure), were bound to the appropriated 
beads and used to co-precipitate (GST PD or pMAL PD) the 
PP1 isoforms from mitotic Hela cells lysate (2.5 mg/PD). This 
was followed by electrophoresis, to which cell lysate was 
also added (Lys), and immunoblotting to detect the PP1 iso-
forms (PP1α, γ1 and δ blot) and the GST- or pMAL-fusion 
proteins (GST blot or pMAL blot). Detection of the unre-
lated FAK protein (FAK blot) in the cell lysates used for the 
GST or pMAL PD assays confirmed the use of equal protein 
amounts. The data presented are representative of multiple 
experiments.
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forms, we compared full-length pRb (GST-Rb) and pRb
deletion mutants in their ability to co-precipitate PP1α, γ
and δ from equal amounts of mitotic HeLa cells extracts.
The mutants employed were big pocket (RbBP, residues
379–928, prepared as GST-RbBP or pMAL-RbBP) and C-
terminus (RbCT, residues 792–928, prepared as pMAL-
RbCT). We found that the entire pRb molecule was
required for maximal association of each PP1 isoforms
(detected with our isoform-specific antibodies [5,25],
whereas GST or pMAL alone did not bind PP1 (Fig. 1). We
also confirmed the previous data [24] that neither Rb-
small pocket (GST-Rb-SP, residues 379–793) nor Rb-N-
terminal (GST-RbNT, residues 1–380) were able to bind
PP1 (not shown).
Association of PP1 from mitotic or asynchronous HeLa cell 
extracts with pRb or Ser/Thr pRb-mutants [Fig 2]
Since PP1 interacts with pRb throughout the cell cycle
[18,22], we compared the binding of all three PP1 iso-
forms from mitotic and asynchronous cell extracts. The
results indicated that their association with pRb was quite
similar (compare WT data in Fig. 2).
All the above experiments used bacterial proteins, indicat-
ing that the targeted sites may attract PP1 even in their
unphosphorylated form. This is similar to what we
observed with the interaction of PP1 and the Ron receptor
[26] or FAK [27]. We next addressed whether the Rb phos-
phorylation sites were involved in the association of PP1
with pRb. To test this hypothesis, we analyzed the ability
of the pRb carrying Ser/Thr-to-Ala mutations of 14 resi-
dues (indicated in the bottom part of Fig 2) to co-precipi-
tate PP1. Surprisingly, we found that mutation of all 14
sites did not affect the ability of pRb to co-precipitate the
PP1 isoforms from mitotic or asynchronous HeLa cells
extracts (Fig. 2). These results support the notion that the
association of PP1 with pRb is not dependent upon the
presence of these Ser/Thr residues.
Isolation of the pRb-directed PP1 holoenzyme obtained 
from a cell extract [Fig 3]
We next sought to determine whether the interaction
between PP1 and pRb involved a PP1-trageting subunit
[1]. For this purpose we used a full-length GST-Rb affinity
column to capture pRb-directed PP1 complexes from
mitotic HeLa cells extract, which were subsequently ana-
lyzed by gel filtration. PP1 eluted from the affinity column
as a single activity peak (Fig. 3A). Immunoblotting of the
pooled peak fractions indicated the presence of all three
PP1 isoforms (Fig. 3A, inset). Following concentration,
the pool was analyzed by gel filtration on FPLC Superose
12 HR 10/30. The PP1 activity peak displayed an approx-
imate 35 000 Mr, supporting our conclusion that PP1 was
present as a free catalytic subunit (Fig. 3B; the experiment
shown is representative of three independent experi-
ments). Limited tryptic-digestion of the affinity column
pool, performed prior to gel filtration, did not change the
elution profile significantly (Fig. 3C), thus further con-
firming the absence of additional PP1 associated proteins.
The small peak that eluted just before the major activity
peak (Fig. 3B), which was removed by trypsin-treatment
(Fig. 3C), may represent a non-specific aggregate, since it
was also found in other PP1 forms that had been obtained
from crude cellular extracts by affinity chromatography
[27]. This experiment was repeated with affinity columns
prepared with GST- or pMAL-RbBP and GST- or pMAL-
RbCT, using mitotic or asynchronous Hela cells extracts
(data not shown). These experiments revealed a single
activity peak of 35,000 Mr for PP1. Taken together, the
results strongly suggest the absence of a PP1 regulatory
Association of cellular PP1 isoforms with wild-type or Ser/ Thr-to-Ala Rb-mutant Figure 2
Association of cellular PP1 isoforms with wild-type or 
Ser/Thr-to-Ala Rb-mutant. GST-Rb, either wild-type 
(WT) or carrying the Ser/Thr-to-Ala mutations (Mut) of the 
sites indicated in the lower part of the figure (further 
described in [31]) or GST, were bound to glutathione-Sepha-
rose beads and used to co-precipitate the PP1 isoforms from 
2.5 mg of mitotic or asynchronous Hela cells extracts. All the 
rest was as in Fig. 1. FAK was used to normalize the amount 
of mitotic and asynchronous cell extracts used, since FAK 
protein did not change throughout the cell cycle. The data 
presented are representative of two independent experi-
ments.
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subunit in the pRb-directed PP1 obtained from either
mitotic or asynchronous HeLa cells.
Interaction of pRb with free PP1 catalytic subunit [Fig. 4]
To further test the hypothesis that the interaction between
pRb and PP1 is a direct one, we investigated the ability of
the PP1 catalytic subunit purified from rabbit muscle (a
mixture of the three isoforms) to associate with pRb or
RbCT. Both full-length Rb and RbCT co-precipitated PP1
catalytic subunit (Fig. 4), supporting the conclusion of a
direct association with PP1. Moreover, a greater associa-
tion between pRb and PP1 was observed compared to the
association between RbCT and PP1, thus confirming the
results obtained with cellular-derived PP1 (Fig. 1).
Reconstitution of a PP1-pRb complex [Fig. 5]
To further confirm the direct interaction between pRb and
PP1, free PP1 catalytic subunit (Mr 35 000) and RbCT
(approx. Mr 14 000 after GST-removal with thrombin)
were incubated in 1:1 molar ratio and subsequently ana-
lyzed by gel filtration. Gel filtration analysis of PP1 and
RbCT alone were also performed. When PP1 and RbCT
were present together, the PP1 activity displayed a single
peak (Fig. 5A, filled circles) eluting slightly ahead of the
PP1 alone peak (open circles), suggesting PP1-RbCT com-
plex formation. This complex formation was confirmed
by the immunoblotting, which detected the presence of
both PP1 and RbCT in the same peak fractions (see PP1
blot and RbCT blot of the PP1+RbCT column fractions,
Fig. 5B). Conversely, both PP1 and RbCT were retarded
when run separately (see PP1 blot and Rb blot of the PP1
and RbCT column fractions, respectively, Fig. 5B). Taken
together, the results further confirmed the ability of PP1
to interact directly with pRb.
Discussion
In the present study we reported that optimal in vitro
interaction of pRb with the three PP1 isoforms found in
cellular extract requires the entire pRb molecule. This
interaction was found to be direct, rather than involving a
PP1-targeting subunit, and did not depend upon the pres-
ence of pRb Ser/Thr residues that are known to be PP1-tar-
gets.
A previous investigation indicated that at mitotic exit all
the three PP1 isoforms dephosphorylated a number of
Ser/Thr Rb sites, which were located in the C-terminal and
N-terminal domains and in the region that links the A and
B small pockets [6]. Additionally, the C-terminal region of
pRb was reported to be both necessary and sufficient for
the interaction with the PP1α isoform, whereas neither
the N-terminal nor the small A/B pocket (which lacks
both the N- and C-terminal domains) bound to PP1α
[24]. The present results demonstrate that the C-terminal
domain interacts with all three PP1 isoforms contained in
cellular extract (Fig. 1). However, both full-length pRb
and Rb-BP displayed greater binding capacity than RbCT
with respect to all the isoforms. This is most likely due to
the presence of additional PP1-binding residues or
domains located outside RbCT and supports the previous
report that at mitotic exit PP1 targets Ser/Thr residues
located throughout the entire molecule [6].
The PP1-pRb interaction did not require phosphorylation
of any site potentially targeted by PP1, since it occurred
also with the non-phosphorylated recombinant pRb
forms. This was not surprising since we had reported a
similar result in the case of the interaction of PP1 with
Ron and FAK [26,27]. More surprisingly was the finding
that point-mutation of up to 14 Ser/Thr sites, most of
which were demonstrated PP1 targets [6], did not affect
PP1 binding. This may indicate that either the sequences
surrounding the phosphorylation sites or other pRb
sequences play a relevant role in PP1-binding. Indeed we
arrived at a similar conclusion in the case of FAK, whereby
mutation of four potential PP1-binding residues in the C-
terminal domain decreased, but did not abolish, PP1-
binding to FAK [27]. In the case of pRb, the presence of
secondary binding-sites was suggested to explain why
RbCT behaved as a non-competitive inhibitor of PP1, in
spite of being a PP1 substrate [24]. Secondary binding
sites were also reported in the case of another PP1 sub-
strate, the K-Cl cotransporter [28], and might be a more
general mechanism required to anchor the PP1 catalytic
subunit when a targeting subunit is not available.
pRb interacts with the PP1 catalytic subunit isoforms
directly. This conclusion is supported by the following
evidence: 1) the PP1 from both mitotic and asynchronous
cell extracts eluted as a single activity peak of approx. 35
000 Mr, representative of free catalytic subunit. The same
result was obtained with the RbBP- or RbCT-directed PP1;
2) limited tryptic digestion did not change the elution
profile; 3) pRb or RbBP was able to associate with purified
PP1 catalytic subunit; 4) a stable complex was reconsti-
tuted from free PP1 catalytic subunit and RbCT. These
properties seem to apply to all three PP1 isoforms, since
they were found to co-associate with pRb in the co-precip-
itation experiments. In addition all three PP1 isoforms
were found in the Rb-directed PP1 activity peak isolated
by affinity chromatography. Taken together, our results
suggest that during mitosis, all the three PP1 isoforms
may associate directly with pRb, ready to perform the
sequential Ser/Thr dephosphorylations occurring at M-to-
G1 transition.
Conclusion
In summary, the work supports the conclusion that full
length pRb is required for optimal interaction with all the
three PP1 isoforms in vitro. Surprisingly, the phosphate-Cancer Cell International 2006, 6:3 http://www.cancerci.com/content/6/1/3
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A – Affinity chromatography of mitotic PP1 on GST-Rb-Sepharose column Figure 3
A – Affinity chromatography of mitotic PP1 on GST-Rb-Sepharose column. Mitotic Hela cells extract (40 mg) was 
applied to a 1 ml GST-Rb-Sepharose column (detailed in the Methods section). The collected fractions were assayed for PP1 
activity and pooled as indicated. One aliquot of the pool was concentrated by precipitation in the presence of 7% TCA and 
subjected to electrophoresis and immunoblotting to detect PP1 isoforms (inset). – B – Gel-filtration of the PP1 eluted 
from the affinity column. Following concentration, one half of the activity pool was applied to an FPLC Superose 12 HR 10/
30 gel filtration column. 0.2 ml fractions were collected, after discarding the first 6 ml, and assayed for PP1 activity. – C – Gel-
filtration of the trypsin-treated PP1 pool. The remaining half of the concentrated activity pool was subjected to limited 
tryptic-proteolysis prior to gel filtration. Molecular weight markers: catalase (250 k), BSA (68 k), ovalbumin (43 k), carbonic 
anhydrase (29 k). The data presented are representative of several experiments (see Results).
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accepting residues on pRb did not appear to direct this
interaction. The association of all three isoforms of PP1
with pRb was a direct one, since no evidence of PP1-asso-
ciated regulatory subunit was detected in the pRb-directed
PP1 activity or required for complex reconstitution.
Methods
Antibodies, enzymes and other chemicals
PMSF, benzamidine, TPCK, leupeptin, protein A-Sepha-
rose, protein A-peroxidase, nocodazole, media and addi-
tives for cell culture were purchased from Sigma Chem.
Co.. Glutathione-Sepharose 4B, the pGEX vectors, anti-
GST antibodies and thrombin were from Amersham Bio-
sciences. Amylose resin, the pMAL-c2E vector and the
restriction enzymes were from New England Biolabs. Taq
DNA polymerase and the rapid DNA ligation kit were
from Roche Molecular Biochemicals. The affinity-purified
anti-pRb polyclonal antibody (C-15, recognizing both
hyper- and hypophosphorylated pRb forms) and the anti-
pMAL antibody were from Santa Cruz. The anti-GST anti-
body was from Amersham Biosciences. The three PP1-iso-
form-specific antibodies (hyperimmune serum) were
raised by us in rabbits injected with C-terminal peptides
[5]. PP1 catalytic (35 000 Mr) was purified from rabbit
muscle [29] and did not contain PP2A.
Plasmid preparations
Full-length GST-pRb, GST-Rb-big pocket (RbBP, residues
379–928), GST-Rb-C-terminal (RbCT, residues 792–928)
were described previously [24,30]. For the pMAL-fusion
proteins of RbBP and RbCT, the amplimers were pro-
duced by PCR using the following synthetic oligonucle-
otides (Primm, I): 5'-GAATTCATGAACACTATCCAACAA-
3' and 5'-GGATCCTCATTTCTCTTCCTTGTT-3' (antisense)
for RbBP; 5'-GAATTCCCTAGTTCACCCTTACGG-3' and
5'-GGATCCTCATTTCTCTTCCTTGTT-3' (antisense) for
RbCT. The template DNA was either RbBP or RbCT cDNA
in pGEX vector [30]. The RbBP fragment was cloned into
the pGEM-T vector, cut at the BamHI sites and subcloned
into the same site of the pMAL-c2E vector. The RbCT frag-
ment was cloned into the pGEM-T vector, cut at the
BamHI and EcoRI sites and subcloned into the same sites
of the pMAL-c2E vector. E. coli BL-21 protease-minus bac-
teria were used for the pMAL- or GST-fusion protein pro-
duction. The phosphorylation sites mutant of full-length
GST-Rb (produced in E. coli Bl21pLys) was described pre-
viously [31].
Expression of fusion proteins in bacteria
For GST-fusion proteins production, the bacteria were
grown at 37°C in LB-Ampicyllin (or 2XYT-Ampicyllin
supplemented with 0.1% w/v glucose and 20 mg/ml chlo-
ramphenicol in the case of E. coli Bl21pLys), induced with
0.1 isopropyl-β-D-thiogalactoside (IPTG) at 37°C for 2 h
or 0.2 mM IPTG at 20°C for 16 h, collected by centrifuga-
tion and resuspended in 25 mM TRIS-HCl, pH 7.5, 150
mM NaCl, 15 mM 2-mercaptoethanol (bacterial lysis
buffer) added with protease inhibitors (0.02 % w/v benz-
amidine, 0.02 % w/v PMSF, 0.02 % w/v TPCK and 4 µg/
ml leupeptine). Following quick freezing and thawing,
0.25 % v/v Triton X-100, 50 U/ml DNase, 10 mM MnCl2
and 10 mM MgCl2 were added, followed by 30 min rota-
tion at 4°C and 10,000 × g centrifugation for 20 min. The
extract thus obtained was either used immediately in pull-
down assays or stored at -20°C.
Cell growth and extracts
Hela cells were grown at 37°C in water-saturated CO2, in
DMEM added with 10 % v/v fetal calf serum (Sigma
Chem. Co.). Following two washes in cold PBS, cells were
lysed in 50 mM TRIS-HCl, pH 7.5, 250 mM NaCl, 5 mM
EDTA, 0.1 % Triton X-100 (cell lysis buffer), 7.5 mM 2-
mercaptoethanol, 1 mM orthovanadate and protease
inhibitors as described for bacterial extracts. Sub-conflu-
ent Hela cells were exposed to 50 ng/ml nocodazole for 18
h. The mitotic cells (approximately 50% of the cells) were
collected by gentle pipetting, washed in cold PBS and
lysed.
Interaction of pRb or RbCT with PP1 catalytic subunit Figure 4
Interaction of pRb or RbCT with PP1 catalytic subu-
nit. PP1 catalytic subunit (purified from muscle as a mixture 
of the three isoforms) was applied to a 0.5 ml column pre-
pared with either GST-Rb-Sepharose or GST-RbCT-Sepha-
rose or GST-Sepharose (further described in the Methods 
section). The PP1-containing fractions were pooled and con-
centrated by precipitation in the presence of 7% TCA. One 
aliquot of each pool was subjected to electrophoresis and 
immunoblotting to detect PP1 (PP1 blot, using a mixture of 
the three isoform-specific antibodies) and GST-Rb, GST-
RbCT or GST (GST blot). PP1 catalytic subunit (30 ng loaded 
on the electrophoresis) is also shown as positive control. 
The data presented are representative of two independent 
experiments.
 Rb    RbCT  GST 
     PP1 blot                                            --PP1
     GST blot
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             __________________Cancer Cell International 2006, 6:3 http://www.cancerci.com/content/6/1/3
Page 7 of 9
(page number not for citation purposes)
A – Gel filtration of the PP1-RbCT complex Figure 5
A – Gel filtration of the PP1-RbCT complex. PP1 catalytic subunit (as in Fig. 4) was incubated with the carboxyl terminal 
region of Rb (obtained from GST-RbCT by thrombin-proteolysis) in 1:1 molar ratio at 4° for 30 min and applied to a Sephacryl 
S400 HR gel filtration column (further described in the Methods section). The column fractions were assayed for PP1 activity 
(filled circles). PP1 (open circles) or RbCT were also run separately on the column (see also part B of the figure). The molecu-
lar weight markers were as in Fig 3, with the addition of ferritin (440 k) and PP1 (35 k). – B – Immunological detection of 
PP1 and RbCT eluted from the gel filtration columns. Either PP1, or the PP1-RbCT complex or RbCT were subjected 
to gel filtration (see part A; here indicated as PP1, PP1+RbCT and RbCT columns). The fractions obtained from the columns 
were concentrated by precipitation and analyzed by electrophoresis and immunoblotting to detect PP1 (PP1 blot, using a mix-
ture of the three isoform-specific antibodies) or RbCT (Rb blot). The data presented are representative of two independent 
experiments.
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Co-precipitation assays and Western blots
GST-proteins from bacterial extracts were bound to 50 µl
of glutathione-Sepharose beads pre-treated with lipid-free
BSA. pMAL-fusion proteins from bacterial extracts were
bound to 50 µl of Amylose resin, according to the manu-
facturer's instructions. After 90 min rotation at 4°C and
three washes with bacterial lysis buffer (added with 0.1
%Triton X-100, 0.02 % w/v benzamidine and 0.02 % w/v
PMSF), the beads were mixed with 2–3 mg of cell extract.
This was followed by incubation at 4°C for 90 min with
shaking, three washes in cell lysis buffer added with 0.02
% w/v benzamidine and 0.02 % w/v PMSF and boiling in
Laemmli buffer. Electrophoresis was on 8.5 % polyacryla-
mide-SDS gel and Immobilon-P membranes (Millipore)
were used for transblotting. Immunoblotting was carried
out with the indicated antibodies, followed by anti rabbit-
peroxidase (Sigma Chem. Co.) and the enhanced chemi-
luminescence ECL system (Amersham Biosciences).
Affinity chromatography and gel filtration
GST- or pMAL-fusion proteins (25 or 50 ml of bacterial
extract) were bound to 1 or 2 ml of Glutathione-Sepha-
rose beads, according to the manufacturer's instructions.
The resin was washed 4 times in bacterial lysis buffer,
mixed with 30–40 mg of cell extract, rotated for 90 min at
4°C, washed extensively with cell lysis buffer containing
25 mM TRIS-HCl, pH 7.5, 150 mM NaCl, 15 mM 2-mer-
captoethanol, 0.02 % w/v benzamidine and 0.02 % w/v
PMSF and transferred to a 2 ml Bio-Rad Poly-prep col-
umn. The column was run at 5.5 ml/h and directly eluted
with cell lysis buffer containing 300 mM NaCll. 0.640 ml
fractions were collected and assayed for PP1 activity with
the substrate [32P]Phosphorylase a [19,23]. 1 unit of PP1
releases 1 nmol of [32P]H3PO4/min at 30°C and is calcu-
lated after subtracting the cpm of blanks without enzyme.
For immunoblotting to detect the PP1 isoforms, the peak
fractions were pooled, concentrated by precipitation in
the presence of 7 % TCA and boiled in Laemmli buffer.
For gel filtration, the peak fractions were pooled, concen-
trated using Amicon Centricon (Millipore) and loaded on
an FPLC Superose 12 HR 10/30 gel filtration column
(Amersham Biosciences), equilibrated in 10 mM imida-
zole, pH 7.5, 5 % glycerol, 0.01 % Brij-35, 100 mM NaCl,
15 mM 2-mercaptoethanol, 0.02 % w/v benzamidine and
0.02 % w/v PMSF. The column was run at 24 ml/h. 0.20
ml fractions were collected after discarding the 6 ml void
volume, and assayed for PP1 activity. An aliquot of the
concentrated pool was treated with trypsin (20 µg/ml) for
15 min at 30°C, followed by excess soybean trypsin inhib-
itor, and analyzed by gel filtration.
Association between PP1 and Rb-CT
GST-RbCT fusion protein (96 ml of bacterial extract) were
coupled to 1 ml of glutathione-Sepharose beads, accord-
ing to the manufacturer's instructions. The resin was
washed 3 times with bacterial lysis buffer and once with
thrombin cleavage buffer containing 50 mM TRIS/HCl,
pH 8.0, 150 mM NaCl and 2.5 mM CaCl2. After centrifu-
gation, the beads were resuspended in 1 ml of thrombin
cleavage buffer containing 48 U of thrombin, shaken at
room temperature for 40 min and centrifuged to collect
the supernatant containing free RbCT (Mr 14 000), which
was then concentrated using Amicon Centricon. PP1 cata-
lytic subunit (Mr 35 000), purified from rabbit muscle as
a mixture of the three isoforms [29], was incubated with
RbCT (1:1 molar ratio) at 4°C for 30 min and then loaded
on a 0.8 × 48 cm Sephacryl S-400 HR gel filtration column
(Amersham Biosciences), equilibrated with 25 mM imi-
dazole, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.1% TX-100,
15 mM mercaptoethanol, 0.02% w/v benzamidine and
0.02% w/v PMSF. The column was run at 10.5 ml/h and
0.26 ml fractions were collected after discarding the void
volume. The fractions were assayed for PP1 activity and
the activity peak fractions were pooled and concentrated
by precipitation in the presence of 7% TCA, followed by
electrophoresis and immunoblotting, to detect PP1 or
RbCT.
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